<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01758705</url>
  </required_header>
  <id_info>
    <org_study_id>P13-709</org_study_id>
    <nct_id>NCT01758705</nct_id>
  </id_info>
  <brief_title>Post Marketing Observational Study on Venezuelan Patients With Psoriasis</brief_title>
  <official_title>Observational Study; Clinical Effectiveness and Impact on Patient Reported Outcomes in Venezuelan Patients With Psoriasis After 16 Weeks of ADA Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to obtain Venezuelan data of clinical effectiveness, impact in the&#xD;
      HRQoL, work productivity and activity impairment in patients with psoriasis using adalimumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PASI 75 (Psoriasis Area and Severity Index score) Response Rate</measure>
    <time_frame>From Week 0 to Week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Percentage of patients with clinical difference in DLQI (Dermatology Life Quality Index) score</measure>
    <time_frame>From Week 0 to Week 16</time_frame>
    <description>Clinical difference is defined by a minimal important difference (MID) in DLQI score between 2.3-5 at 16 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change of PASI score</measure>
    <time_frame>From week 0 to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of DLQI score</measure>
    <time_frame>From week 0 to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Psoriatic Arthritis Response Criteria (PsARC) score</measure>
    <time_frame>From week 0 to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of Hospital Anxiety and Depression Score (HADS)</measure>
    <time_frame>From week 0 to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change en Work Productivity and Activity Impairment (WPAI)-Psoriasis score</measure>
    <time_frame>From week 0 to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to week 16</time_frame>
    <description>Occurrence of SAEs including tuberculosis, other opportunistic infections and cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation of adalimumab for any reason.</measure>
    <time_frame>Up to week 16</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Moderate to Severe Chronic Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Cohort 1</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects male or female with moderate to severe chronic plaque psoriasis with or without&#xD;
        psoriatic arthritis. Patients with history of psoriatic arthritis or articular symptoms&#xD;
        must be evaluated by a Rheumatologist.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with moderate to severe chronic plaque psoriasis, with or without psoriatic&#xD;
             arthritis, who have the indication for adalimumab because they need systemic therapy&#xD;
             or because they have had failure to phototherapy, or to other systemic or topical&#xD;
             treatments&#xD;
&#xD;
          -  Subjects that are not receiving biologic therapy in the last 12 weeks or classical&#xD;
             therapy in the past 4 weeks and/or phototherapy in the last 2 weeks. Topical therapy&#xD;
             will be allowed, to a constant dose and will not be used within 24 hours prior to the&#xD;
             visit&#xD;
&#xD;
          -  Patients under previous treatment with any experimental drug will have a minimum&#xD;
             washout period of five half-lives&#xD;
&#xD;
          -  Subjects must be capable to understand and willing to give a written informed consent&#xD;
             form to release information and to comply with the requirements of the study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects should not be enrolled if they cannot be treated in accordance with the local&#xD;
             product label approved in Venezuela&#xD;
&#xD;
          -  Subjects enrolled into another study or under treatment with an investigational&#xD;
             product&#xD;
&#xD;
          -  History of viral hepatitis B infection or HIV&#xD;
&#xD;
          -  History of neurologic symptoms suggestive of central nervous system demyelinating&#xD;
             disease&#xD;
&#xD;
          -  History of cancer or lymphoproliferative disease (other than successfully treated&#xD;
             non-melanoma skin cancer or localized carcinoma in situ of the cervix)&#xD;
&#xD;
          -  Active TB infection before initiating adalimumab treatment or latent TB infection not&#xD;
             able to complete prophylactic treatment&#xD;
&#xD;
          -  Pregnant or lactating female. Pregnancy will be tested before entering the study in&#xD;
             fertile women. Women in fertile age must be advised by the physician, to use a&#xD;
             clinically accepted contraceptive method (contraceptive pills, IUDs, barrier devices&#xD;
             as condoms or abstinence)&#xD;
&#xD;
          -  History of congestive heart failure (CHF)&#xD;
&#xD;
          -  Any another condition that according to the criteria of the participating investigator&#xD;
             represents an obstacle for study conduction and / or subjects to an unacceptable risks&#xD;
&#xD;
          -  Subjects with active infection including chronic or localized infections until&#xD;
             infections are controlled&#xD;
&#xD;
          -  History of sensitive to latex or other component of the syringe&#xD;
&#xD;
          -  Subjects who requires concomitant phototherapy and systemic therapy during adalimumab&#xD;
             therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natali Serra-Bonett, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <removed_countries>
    <country>Venezuela</country>
  </removed_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>December 26, 2012</study_first_submitted>
  <study_first_submitted_qc>December 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2013</study_first_posted>
  <last_update_submitted>November 26, 2016</last_update_submitted>
  <last_update_submitted_qc>November 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Related to Health Quality of Life</keyword>
  <keyword>Patient Reported Outcomes</keyword>
  <keyword>Venezuelan Patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

